Imricor Medical Systems, Inc.
ASX:IMR Rapport sur les actions
Capitalisation boursière : AU$235.1m
Imricor Medical Systems Résultats passés
Passé contrôle des critères 0/6 Les bénéfices de Imricor Medical Systems ont diminué à un taux annuel moyen de -12.9%, tandis que le secteur Medical Equipment a vu ses bénéfices augmenter de en à 8.3% par an. Les revenus ont augmenté de en à un taux moyen de 2.1% par an.
Informations clés
-12.9%
Taux de croissance des bénéfices
9.6%
Taux de croissance du BPA
Medical Equipment Croissance de l'industrie 5.8% Taux de croissance des recettes 2.1% Rendement des fonds propres n/a Marge nette -2,458.3% Dernière mise à jour des bénéfices 30 Jun 2024
Mises à jour récentes des performances passées
Imricor Medical Systems, Inc. to Report First Half, 2024 Results on Aug 28, 2024 Aug 09
Imricor Medical Systems, Inc. to Report Q1, 2024 Results on Apr 30, 2024 Apr 23
Full year 2023 earnings released: US$0.14 loss per share (vs US$0.12 loss in FY 2022) Mar 01
Imricor Medical Systems, Inc. to Report Fiscal Year 2023 Results on Feb 29, 2024 Feb 27
First half 2023 earnings released: US$0.061 loss per share (vs US$0.068 loss in 1H 2022) Aug 25
Imricor Medical Systems, Inc. to Report First Half, 2023 Results on Aug 23, 2023 Aug 15
Afficher toutes les mises à jour
Imricor Medical Systems, Inc. to Report First Half, 2024 Results on Aug 28, 2024 Aug 09
New major risk - Revenue and earnings growth Aug 08
New major risk - Shareholder dilution Jul 28
New major risk - Revenue and earnings growth Jul 02
Independent Non-Executive Director recently bought AU$73k worth of stock May 09
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Imricor Medical Systems, Inc.'s (ASX:IMR) CEO For Now May 08
Imricor Medical Systems, Inc. to Report Q1, 2024 Results on Apr 30, 2024 Apr 23
Imricor Medical Systems, Inc., Annual General Meeting, May 15, 2024 Apr 09 Imricor Medical Systems, Inc. has completed a Follow-on Equity Offering in the amount of AUD 15.135297 million. Apr 02
Insufficient new directors Apr 01
New major risk - Revenue and earnings growth Mar 04
Full year 2023 earnings released: US$0.14 loss per share (vs US$0.12 loss in FY 2022) Mar 01
Imricor Medical Systems, Inc. to Report Fiscal Year 2023 Results on Feb 29, 2024 Feb 27
New major risk - Revenue and earnings growth Feb 12 Imricor Medical Systems, Inc. has filed a Follow-on Equity Offering in the amount of AUD 15 million. Feb 02
First half 2023 earnings released: US$0.061 loss per share (vs US$0.068 loss in 1H 2022) Aug 25
New major risk - Revenue and earnings growth Aug 25
New major risk - Share price stability Aug 17 Imricor Medical Systems, Inc. announced that it has received AUD 2.861607 million in funding Aug 17
Imricor Medical Systems, Inc. to Report First Half, 2023 Results on Aug 23, 2023 Aug 15 Imricor Medical Systems, Inc. announced that it has received AUD 1.457143 million in funding Jul 18
Does Imricor Medical Systems (ASX:IMR) Have A Healthy Balance Sheet? Jun 17
New minor risk - Share price stability Jun 17
Key Executive recently bought AU$195k worth of stock Mar 14
Full year 2022 earnings: Revenues miss analyst expectations Feb 24
Imricor Medical Systems, Inc. to Report Fiscal Year 2022 Results on Feb 22, 2023 Feb 08
Imricor Medical Systems, Inc. Receives IDE Approval from US FDA Jan 24
Forecast to breakeven in 2025 Dec 31
Imricor Medical Systems, Inc. Receives the First of Two Required Approvals to Commence the Vision-MR Ablation of VT or VISABL-VT Clinical Trial Dec 16 Imricor Medical Systems, Inc. announced that it expects to receive $5 million in funding from KAHR Foundation Dec 13
President recently bought AU$76k worth of stock Nov 16
President recently bought AU$76k worth of stock Nov 12
Imricor Medical Systems, Inc. to Report Q3, 2022 Results on Oct 27, 2022 Oct 24
Imricor Medical Systems, Inc. Submits Application for Approval to Commence A Real-Time iCMR-Guided Ventricular Tachycardia (VT) Ablation Clinical Trial Sep 19 Imricor Medical Systems, Inc. announced that it has received AUD 2.947049 million in funding Sep 15
First half 2022 earnings released: US$0.068 loss per share (vs US$0.079 loss in 1H 2021) Sep 01
Imricor Medical Systems, Inc. to Report First Half, 2022 Results on Aug 25, 2022 Aug 17
Imricor Medical Systems, Inc. to Report Q4, 2022 Results on Jul 28, 2022 Jul 19
Here's Why Imricor Medical Systems (ASX:IMR) Must Use Its Cash Wisely Jul 08
Imricor Medical Systems, Inc. Completes its Preclinical Work to Support Submission for Approval to Initiate VT Clinical Trial in Europe Jun 29
Imricor Medical Systems, Inc., Annual General Meeting, May 03, 2022 Apr 08
Will Imricor Medical Systems (ASX:IMR) Spend Its Cash Wisely? Mar 23
Full year 2021 earnings: EPS and revenues miss analyst expectations Feb 25
Consensus revenue estimates fall by 57% Feb 25
Imricor Medical Systems, Inc. Announces Executive Changes Feb 11
Consensus forecasts updated Feb 01
Imricor Medical Systems, Inc. to Report Fiscal Year 2021 Results on Feb 24, 2022 Jan 28
Imricor Medical Systems, Inc. Files Application for an Investigational Device Exemption from US Food and Drug Administration Nov 24
First half 2021 earnings released: US$0.079 loss per share (vs US$0.056 loss in 1H 2020) Aug 27
No longer forecast to breakeven Jul 30
Consensus forecasts updated Jul 30
We're Hopeful That Imricor Medical Systems (ASX:IMR) Will Use Its Cash Wisely May 09
Non-Executive Director has left the company Mar 04
Imricor Medical Systems, Inc. Announces Board Changes Mar 04
When Will Imricor Medical Systems, Inc. (ASX:IMR) Turn A Profit? Feb 28
Full year 2020 earnings released: US$0.11 loss per share (vs US$0.22 loss in FY 2019) Feb 26
Revenue beats expectations Feb 26
New 90-day low: AU$2.16 Feb 17
Imricor Medical Systems, Inc. to Report Fiscal Year 2020 Results on Feb 25, 2021 Feb 01
We Think Imricor Medical Systems (ASX:IMR) Needs To Drive Business Growth Carefully Jan 24
Imricor Medical Systems, Inc. Appoints Gregg Stenzel as COO Dec 30
Imricor Signs Supply and Sales Agreement with Osypka Dec 11
What Is The Ownership Structure Like For Imricor Medical Systems, Inc. (ASX:IMR)? Dec 02
Imricor Medical Systems, Inc. Signs New Purchase Agreement Nov 27
New 90-day high: AU$2.78 Oct 30
Imricor Medical Systems, Inc. (ASX:IMR) signed an agreement to acquire Schleswig-Holstein University Medical Centre in Germany. Oct 29
Imricor Medical Systems, Inc. to Commence Clinical Procedures After Receiving Ethics Committee Approval to Use Isuite Software Oct 12
Imricor Awards National Institutes of Health Contract Oct 05
Imricor Medical Systems, Inc. Signs Purchase Agreement with MUMC Sep 30
New 90-day high: AU$2.30 Sep 23
Leipzig Heart Centre Signs Purchase Agreement with Imricor Medical Systems Sep 21
New 90-day high - AU$2.15 Sep 08
Earnings released Aug 25
What You Need To Know About Imricor Medical Systems, Inc.'s (ASX:IMR) Investor Composition Aug 18
Imricor Medical Systems, Inc. to Report Fiscal Year 2020 Results on Aug 25, 2020 Aug 04
Imricor Medical Systems, Inc. to Report Q2, 2020 Results on Jul 29, 2020 Jul 21
New 90-day high - AU$1.73 Jul 20
Analysts Expect Breakeven For Imricor Medical Systems, Inc. (ASX:IMR) Jun 25
Ventilation des recettes et des dépenses
Comment Imricor Medical Systems gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes ASX:IMR Recettes, dépenses et bénéfices (USD Millions ) Date Recettes Les revenus Dépenses G+A Dépenses de R&D 30 Jun 24 1 -20 7 8 31 Mar 24 1 -21 7 8 31 Dec 23 1 -23 8 8 30 Sep 23 1 -20 8 8 30 Jun 23 0 -17 8 7 31 Mar 23 1 -17 8 8 31 Dec 22 1 -17 8 8 30 Sep 22 1 -18 8 9 30 Jun 22 1 -20 9 9 31 Mar 22 1 -20 9 10 31 Dec 21 1 -20 9 10 30 Sep 21 1 -18 8 9 30 Jun 21 1 -17 7 8 31 Mar 21 1 -15 7 7 31 Dec 20 1 -12 6 6 30 Sep 20 1 -13 5 5 30 Jun 20 1 -14 5 4 31 Mar 20 1 -14 4 4 31 Dec 19 1 -13 3 4 30 Sep 19 1 -11 3 4 30 Jun 19 0 -8 2 4 31 Mar 19 1 -7 2 4 31 Dec 18 1 -5 2 4 31 Dec 17 0 -5 2 4 31 Dec 16 1 -4 2 3
Des revenus de qualité: IMR n'est actuellement pas rentable.
Augmentation de la marge bénéficiaire: IMR n'est actuellement pas rentable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: IMR n'est pas rentable et les pertes ont augmenté au cours des 5 dernières années à un rythme de 12.9% par an.
Accélération de la croissance: Impossible de comparer la croissance des bénéfices de IMR au cours de l'année écoulée à sa moyenne sur 5 ans car elle n'est actuellement pas rentable
Bénéfices par rapport au secteur d'activité: IMR n'est pas rentable, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Medical Equipment ( 18.7% ).
Rendement des fonds propres
ROE élevé: Le passif IMR dépasse son actif, il est donc difficile de calculer son rendement des capitaux propres .
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
